Chinese artificial intelligence driven drug discovery firm XtalPi Holdings has projected its first full year profit following a sharp rise in revenue, signaling growing commercial traction for AI powered pharmaceutical research in China. The Shenzhen based company said it expects to report a
China’s biotechnology sector is entering a new phase of financial maturity as companies move beyond heavy reliance on licensing agreements and tap deeper pools of domestic and international capital. Strong equity market performance, regulatory reforms and expanding innovation pipelines are reshaping the funding
Chinese biotechnology companies are accelerating their push into global markets, with Shanghai based Harbour BioMed announcing a partnership valued at more than US$1.2 billion to advance one of its clinical stage antibody therapies outside mainland China. The agreement underscores a broader shift in
China’s accelerating biotechnology expansion is driving an unexpected cost surge in one of the industry’s most critical research resources, laboratory monkeys used in preclinical drug testing. Prices for experimental monkeys have climbed to around 140,000 yuan per animal, a level that now exceeds
China’s biotechnology sector is on track for another record year in licensing activity as global pharmaceutical companies intensify their search for innovative drug candidates to offset looming patent expirations and rising research costs. Data from industry tracker Pharmcube shows that out licensing deals
Chinese healthcare companies are accelerating overseas expansion plans as mainland firms increase their global footprint and send more employees abroad. The strategy is focused on serving Chinese expatriate communities in regions such as the Middle East and Southeast Asia, where language familiarity and
WuXi Biologics has projected a sharp increase in full year earnings for 2025, signaling renewed momentum for China’s leading biologics contract development and manufacturing organization. The company expects profit attributable to equity shareholders to rise by 46.3 percent to approximately 4.91 billion yuan,
Chinese authorities have formally charged Leon Wang, the former regional head of AstraZeneca in China, more than a year after he was detained in connection with investigations into the pharmaceutical group’s operations in the country. The development marks a significant step in a
Mainland Chinese investors have stepped up buying of Hong Kong listed pharmaceutical and biotech stocks, riding a renewed wave of overseas licensing agreements that is reshaping how China’s drug developers access global markets. The shift highlights growing confidence in innovative drug makers at
A deadly explosion at a small biotechnology facility in northern China has left eight people dead, drawing renewed attention to industrial safety standards and regulatory enforcement in the country’s manufacturing and life sciences sectors. The blast occurred in the early hours of Saturday
